NICE backing for Perjeta in breast cancer after Roche cuts price

17 November 2016

The National Institute of Health and Care Excellence (NICE) has recommended the use of Swiss pharma giant Roche’s (ROG: SIX) cancer drug Perjeta (pertuzumab) on the National Health Service (NHS) in England and Wales.

A discount to the price of pertuzumab agreed with the company was an important factor in enabling the NICE to overturn its earlier provisional decision not to recommend the drug for treating HER2-positive breast cancer, the cost-effectiveness watchdog has said.

"We welcome the company’s offer to share the long-term financial risks of a positive recommendation for the NHS by providing pertuzumab at a discounted price"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK